Drug Trial Radar · NCT07892625
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
338
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Sep 15, 2028
Study completion Sep 15, 2029
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.
Conditions
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
HS-20093 for InjectionDrug
The patient will be treated with HS-20093.
ZG006Drug
The patient will be treated with ZG006.
Adebrelimab InjectionDrug
The patient will be treated with adebrelimab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximum tolerated dose (MTD) or maximum applicable dose (MAD) for combination treatmentsTime frame: Up to day 21 or 28 from the first dose
- The incidence rate of dose-limiting toxicities (DLT) events in combination treatmentsTime frame: Up to day 21 or 28 from the first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.